Veverimer

Phase 3Small molecule

RRenibus Therapeutics, Inc.

Veverimer is one of 9 small molecule programs targeting Bone Resorption. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone ResorptionActive, not recruiting

Metabolic AcidosisActive, not recruiting

CKDRecruiting

Bone ResorptionPhase 1

Active, not recruiting

Metabolic AcidosisPhase 3

Active, not recruiting

CKDPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Bone Resorption

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

1 2

Zometa

Pfizer

Phase 3

1 3

Veverimer

RRenibus Therapeutics, Inc.

Phase 3

1 4

Prolia

Amgen

Preclinical

1 5

Platelet Rich Plasma

ZZagazig University

Phase 1

1 6

Humira

CCelltrion

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

CKD

NCT07355062

Q2 2028

Phase 1Not yet recruiting

Bone Resorption

NCT07473713

Clinical

Trials by Indication[1]

Bone Resorption1 trial

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

Not yet recruiting·TTufts Medical Center·Phase 1·NCT07473713·60 enrolled

CKD1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis

Recruiting·RRenibus Therapeutics, Inc.·Phase 3·NCT07355062·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Veverimer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Veverimer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Veverimer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Renibus Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRenibus Therapeutics, Inc.

Veverimer

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Trials by Indication[1]

Bone Resorption1 trial

CKD1 trial

References

Drug Info

Quick Facts

Related News